HUTCHMED (China) Limited will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026. The announcement is scheduled for 7:00 am Eastern Daylight Time (EDT), 12:00 noon British Summer Time (BST), and 7:00 pm Hong Kong Time (HKT). The company operates as an innovative, commercial-stage, biopharmaceutical firm focused on targeted therapies and immunotherapies for cancer and immunological diseases.

Management will conduct two webcast presentations to discuss the interim results, followed by Q&A sessions. The English webcast is set for July 30, 2026, at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will take place at 8:30 am HKT on Friday, July 31, 2026, which corresponds to 1:30 am BST / 8:30 pm EDT on July 30, 2026.

Both webcasts will be accessible live via the company website at www.hutch-med.com/event/ . The presentation materials will be available for download shortly before the webcast begins. A replay of the events will also be hosted on the website shortly after the conclusion of the sessions.

Key Event Details

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) has focused on bringing drug candidates from in-house discovery to patients globally. Its first three medicines are marketed in China, with the first also approved in the US, Europe, and Japan.

HUTCHMED (China) Limited announced results from a pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (ICC). The data, presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, demonstrated a clinically meaningful objective response rate of 42.5% and a median overall survival of 16.6 months. These findings support fanregratinib as a potential new treatment option for pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements.

Supported by the study data, a New Drug Application (NDA) for fanregratinib was accepted for review and granted priority review by the China National Medical Products Administration (NMPA) in December 2025. The application targets the treatment of adult patients with advanced, metastatic, or unresectable ICC with FGFR2 fusion/rearrangement who have previously received systemic therapy.

Clinical Trial Results

The single-arm, multi-center, open-label Phase II trial was conducted across 53 sites in China. All enrolled patients had received at least one line of systemic therapy, including chemotherapy, and 72% had prior immunotherapy exposure. The study met its primary endpoint, showing an Independent Review Committee (IRC)-assessed objective response rate (ORR) of 42.5% (95% CI: 30.0%–53.6%).

Key secondary endpoints indicated consistent clinical activity and rapid onset of action. The median time to response was 1.4 months. Additional efficacy metrics are detailed in the table below:

Safety Profile

Fanregratinib exhibited a manageable safety profile consistent with the known mechanism of selective FGFR inhibitors. Drug-related adverse events of Grade 3 or greater were reported in 48.3% of patients. The most common events were elevations in liver enzymes and palmar-plantar erythrodysesthesia syndrome (PPES). Treatment discontinuation due to drug-related adverse events occurred in 2.2% of patients, with no treatment-related deaths recorded.

Professor Jianming Xu of the Chinese PLA General Hospital and leading Principal Investigator of the study emphasized the significance of the results. "The objective response rate and survival metrics achieved by fanregratinib clearly support its therapeutic value as a potent, selective oral treatment option," he stated.